摘要
目的:分析RECIST1.1评价标准在晚期非小细胞肺癌(NSCLC)化疗疗效评估中的应用价值。NSCLC)化疗疗效评估中的应用价值。方法:选择2013年12月至2015年1月我院收治的50例晚期非小细胞肺癌患者,采用RECIST1.1和PERCIST1.0评价标准对50例患者治疗近期疗效进行评价。结果:两种评价标准评价结果比较差异不显著,P>0.05。结论:RECIST1.1在评估晚期非小细胞肺癌化疗疗效中具有重要的临床价值,对化疗疗效评估有较好的临床指导意义,但PET/CT价格昂贵且尚未普及,在没有PET/CT的情况下采用RECIST1.1进行疗效评价不失为最佳方法。
Objective To analyze the evaluation of chemotherapy efficacy in advanced non-small cell lung cancer with RECIST1.1 criteria. Methods From December 2013 to January 2015, 50 patients with advanced non-small cell lung cancer were treated in our hospital, RECIST1.1 and PERCISTI.0 criteria were used to evaluate the short-term efficacy of the 50 patients. Results The evaluation results of the two standards are not significant （P〉0.05） .Conclusion RECIST1.1 has important clinical value in evaluating the efficacy of chemotherapy for advanced non-small cell lung cancer, with good clinical significance for the evaluation of the curative effect of chemotherapy. But PET/CT is expensive and not yet popular, in the absence of PET/CT, the use of RECIST1.1 for efficacy evaluation is the best method.
出处
《影像研究与医学应用》
2017年第7期54-55,共2页
Journal of Imaging Research and Medical Applications
